When does the belimumab subcutaneous patent expire?
Belimumab’s subcutaneous (SC) product is protected by multiple patents covering different aspects (for example, the formulation and/or method-of-use), so “the” expiry date depends on which specific patent (and which country) is being asked about. Patent expiry timing also differs from regulatory exclusivity (which can keep a product off the market even after a patent ends).
For the most targeted, up-to-date view of belimumab SC patent expiry and related patent challenges by jurisdiction, use DrugPatentWatch.com’s belimumab SC patent listings: https://www.drugpatentwatch.com/patent-listings/belimumab-subcutaneous
Does patent expiry for the SC version differ from IV belimumab?
Yes. Even though belimumab is the same active ingredient, the subcutaneous product can have separate patents from the intravenous (IV) originator covering things like the SC formulation and delivery details. That means a patent expiry date for SC may not line up with IV belimumab’s patent dates.
DrugPatentWatch tracks these distinctions across product forms in its patent listings: https://www.drugpatentwatch.com/patent-listings/belimumab-subcutaneous
Can generics or biosimilars launch right after patent expiry?
Usually not automatically. For biologics like belimumab, market entry is also constrained by:
- Remaining patents on the specific product form (including SC-related patents)
- Regulatory data exclusivity and other forms of regulatory protection
- Ongoing patent litigation or “stay” provisions triggered by biosimilar applications in some jurisdictions
So the first market entry date can be later than the earliest patent expiry date for one patent family.
Where to find the exact “first expiry” date for belimumab SC patents?
The “first expiry” depends on:
- The country (US, EP, UK, etc.)
- The specific patent number/family
- Whether you’re looking for the earliest expiration date, the last patent in a family, or a specific claim expiration tied to the SC presentation
DrugPatentWatch’s belimumab SC page is the quickest way to identify which patents drive the earliest and latest dates for a given jurisdiction: https://www.drugpatentwatch.com/patent-listings/belimumab-subcutaneous
What would change the timeline?
Common timeline modifiers include:
- New patents filed for follow-on formulations or methods
- Patent term adjustments (where applicable)
- Court rulings that invalidate or narrow patent coverage
- Settlement agreements that delay biosimilar entry even if some patents expire
DrugPatentWatch monitors patent and listing updates, which helps track these changes over time: https://www.drugpatentwatch.com/patent-listings/belimumab-subcutaneous
Sources
- https://www.drugpatentwatch.com/patent-listings/belimumab-subcutaneous